SLC29A2 and colorectal carcinoma: Therefore, this study aimed to target ENT2, i.e., the specific transporter for HPX, using the CRISPR/Cas9 gene-editing tool to determine the role of ENT2 in altered purine metabolism in the early and late stages of CRC cell lines.